Published in Angiogenesis on January 31, 2014
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | NCT00334282
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma | NCT00111007
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med (2016) 1.55
Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2. Cell Rep (2015) 1.17
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell Rep (2016) 1.03
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med (2017) 0.98
Apatinib for molecular targeted therapy in tumor. Drug Des Devel Ther (2015) 0.98
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2015) 0.94
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. J Natl Cancer Inst (2016) 0.92
The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol (2016) 0.89
CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer. Oncotarget (2015) 0.87
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res (2015) 0.87
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget (2016) 0.86
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol (2016) 0.85
Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Drug Des Devel Ther (2015) 0.85
Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data. Biol Direct (2016) 0.84
Physiological Capillary Regression is not Dependent on Reducing VEGF Expression. Microcirculation (2016) 0.84
Transient receptor potential canonical 4 and 5 proteins as targets in cancer therapeutics. Eur Biophys J (2016) 0.84
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia. Cancer Microenviron (2015) 0.84
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol (2016) 0.83
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer (2014) 0.83
Compensatory angiogenesis and tumor refractoriness. Oncogenesis (2015) 0.83
Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. Am J Nucl Med Mol Imaging (2015) 0.83
Soy and breast cancer: focus on angiogenesis. Int J Mol Sci (2015) 0.82
A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer (2014) 0.82
Host deficiency in caveolin-2 inhibits lung carcinoma tumor growth by impairing tumor angiogenesis. Cancer Res (2014) 0.81
Damage effect of high-intensity focused ultrasound on breast cancer tissues and their vascularities. World J Surg Oncol (2016) 0.80
Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Oncotarget (2016) 0.80
Anti-angiogenic alternatives to VEGF blockade. Clin Exp Metastasis (2015) 0.79
Plasma angiopoietin-2 is persistently elevated after non-small cell lung cancer surgery and stimulates angiogenesis in vitro. Medicine (Baltimore) (2016) 0.79
Dihydroartemisinin inhibits vascular endothelial growth factor-induced endothelial cell migration by a p38 mitogen-activated protein kinase-independent pathway. Exp Ther Med (2014) 0.79
Mechanisms of vascularization in murine models of primary and metastatic tumor growth. Chin J Cancer (2016) 0.79
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging (2017) 0.78
VEGF-A isoform-specific regulation of calcium ion flux, transcriptional activation and endothelial cell migration. Biol Open (2015) 0.78
Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived Cells. Cureus (2016) 0.78
Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res (2015) 0.78
Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J Med Paediatr Oncol (2014) 0.78
MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression. Oncotarget (2016) 0.77
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harb Perspect Med (2016) 0.77
Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One (2016) 0.77
Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells. Int J Mol Sci (2016) 0.77
Relative Computed Tomography (CT) Enhancement Value for the Assessment of Microvascular Architecture in Renal Cell Carcinoma. Med Sci Monit (2017) 0.77
NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and Neoangiogenesis. Sci Rep (2016) 0.77
Correlations of vascular architecture and angiogenesis with pituitary adenoma histotype. Int J Endocrinol (2014) 0.77
Depot-Based Delivery Systems for Pro-Angiogenic Peptides: A Review. Front Bioeng Biotechnol (2015) 0.77
Angiogenesis dependent characteristics of tumor observed on rabbit VX2 hepatic carcinoma. Int J Clin Exp Pathol (2015) 0.77
Identification of novel vascular targets in lung cancer. Br J Cancer (2014) 0.77
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget (2016) 0.76
Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget (2016) 0.76
Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells. Pharmaceutics (2015) 0.76
Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes. Int J Nanomedicine (2016) 0.76
Antiangiogenic and Neurogenic Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and In Vivo. Biomed Res Int (2015) 0.76
Targeting tumor vasculature through oncolytic virotherapy: recent advances. Oncolytic Virother (2015) 0.75
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation. Sci Rep (2017) 0.75
Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo. Tumour Biol (2015) 0.75
Role of caveolin-2 in subcutaneous tumor growth and angiogenesis associated with syngeneic mouse Lewis lung carcinoma and B16 melanoma models. Cancer Cell Microenviron (2015) 0.75
Assessing metastasis risk after pre-operative anti-angiogenic therapy. EMBO Mol Med (2014) 0.75
(18)F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemother Pharmacol (2016) 0.75
Effects of endothelial cell proliferation and migration rates in a computational model of sprouting angiogenesis. Sci Rep (2016) 0.75
Immunohistochemical analysis of the mechanistic target of rapamycin and hypoxia signalling pathways in basal cell carcinoma and trichoepithelioma. PLoS One (2014) 0.75
Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci (2017) 0.75
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer. Oncotarget (2016) 0.75
Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. PPAR Res (2017) 0.75
Adaptation to antiangiogenic therapy in neurological tumors. Cell Mol Life Sci (2015) 0.75
Transcriptional and Post-Transcriptional Regulation of Thrombospondin-1 Expression: A Computational Model. PLoS Comput Biol (2017) 0.75
Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic-Cell-Induced Bone Marrow Angiogenesis. Adv Healthc Mater (2016) 0.75
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics (2017) 0.75
Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget (2017) 0.75
A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun (2017) 0.75
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer. Aging (Albany NY) (2016) 0.75
In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: The Performance of Different Selection Strategy in Selecting Virtual Screening Candidates. Sci Rep (2016) 0.75
Multi-scale mathematical modelling of tumour growth and microenvironments in anti-angiogenic therapy. Biomed Eng Online (2016) 0.75
Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility. BMC Cancer (2016) 0.75
Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. J Exp Med (2017) 0.75
New cancer therapies and jaw necrosis. Br Dent J (2015) 0.75
Looking beyond the cancer cell for effective drug combinations. Genome Med (2016) 0.75
Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game. PLoS One (2017) 0.75
Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization. Medchemcomm (2016) 0.75
DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties. Mol Oncol (2017) 0.75
Therapeutic uses of epicatechin in diabetes and cancer. Vet World (2017) 0.75
Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res (2017) 0.75
A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations. Invest New Drugs (2017) 0.75
Epithelial-Mesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol (2017) 0.75
Emerging molecular targets and therapy for cholangiocarcinoma. World J Gastrointest Oncol (2017) 0.75
Dextran-Catechin inhibits angiogenesis by disrupting copper homeostasis in endothelial cells. Sci Rep (2017) 0.75
Fine-Tuning Tumor Endothelial Cells to Selectively Kill Cancer. Int J Mol Sci (2017) 0.75
Pharmacological blockade of cholesterol trafficking by cepharanthine in endothelial cells suppresses angiogenesis and tumor growth. Cancer Lett (2017) 0.75
Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment. F1000Res (2017) 0.75
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Invest New Drugs (2017) 0.75
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Inflammation and cancer. Nature (2002) 53.78
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 35.36
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell (2009) 13.09
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Putting tumours in context. Nat Rev Cancer (2001) 12.37
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Tumor angiogenesis. N Engl J Med (2008) 11.30
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 10.37
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest (2003) 8.34
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol (2009) 7.80
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol (2008) 6.42
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med (1996) 6.11
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol (2012) 5.86
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell (2007) 5.09
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol (2010) 4.81
Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (2006) 4.79
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2011) 4.52
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol (2012) 4.47
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Effect of p53 status on tumor response to antiangiogenic therapy. Science (2002) 4.41
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2001) 4.22
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med (2012) 4.10
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82
Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell (2013) 3.75
A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature (2008) 3.74
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol (2013) 3.71
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol (2010) 3.67
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J (2003) 3.62
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol (2006) 3.53
Tumor angiogenesis: past, present and the near future. Carcinogenesis (2000) 3.50
Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer (2010) 3.48
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A (2011) 3.48
Signal transduction by vascular endothelial growth factor receptors. Biochem J (2011) 3.47
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer (2008) 3.46
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol (2009) 3.43
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell (2009) 3.27
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 3.24
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell (2012) 3.19
Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol (2006) 1.74
Mechanism of tumour vascularization in experimental lung metastases. J Pathol (2014) 1.55
Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res (2003) 1.42
The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res (2013) 1.35
FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res (2011) 1.29
Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion. J Pathol (2005) 1.16
Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem (2009) 1.15
The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res (2013) 1.04
Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. Cancer Res (2012) 1.02
Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol (2010) 1.02
Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis (2012) 1.00
Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. J Biol Chem (2013) 0.94
Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist (2011) 0.87
Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. Angiogenesis (2008) 0.84